Thrombotic microangiopathy due to thrombotic thrombocytopenia should be suspected in a patient with otherwise unexplained thrombocytopenia and anemia, even without fever, renal dysfunction or ...

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation. X. Long Zheng, MD, PhD: What is acquired TTP? TTP ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

This report describes a newborn who presented with hyperbilirubinemia and thrombocytopenia. The patient recovered after treatment with antibiotics, phototherapy, and a platelet transfusion. Analysis ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Purpose. A case of a patient who developed thrombotic thrombocytopenic purpura (TTP) after consuming a weight-loss product containing green tea is reported. Summary. A 38-year-old, 68-kg Caucasian ...

Inhibitory autoantibodies against ADAMTS13, a metalloproteinase enzyme that cleaves von Willebrand factor, are associated with the majority of nonfamilial cases of thrombotic thrombocytopenic purpura ...

Please provide your email address to receive an email when new articles are posted on . In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and ...

The impaired reactivity may play a role in organ injury, the authors suggested, among patients who have immune-mediated thrombotic thrombocytopenic purpura (iTTP). People with immune-mediated ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has on 12th May, 2025 approved rADAMTS13 (Adzynma), the first UK treatment to treat congenital thrombotic thrombocytopenic purpura (CTTP) ...